Patents by Inventor Mark Lankau

Mark Lankau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE AND AMORPHOUS 4-CYANO-N--N-PYRIDIN-2-YL-BENZAMIDE HYDROCHLORIDE
    Publication number: 20090192311
    Abstract: The present invention is directed to crystal and amorphous forms of the 5-HT1A receptor antagonist 4-cyano-N-{(2R)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-N-pyridin-2-yl-benzamide hydrochloride, as well as compositions thereof and methods of using the same.
    Type: Application
    Filed: February 3, 2009
    Publication date: July 30, 2009
    Inventors: Eric N.C. Browne, Michel Bernatchez, Mark Lankau, Abdolsamad Tadayon, Anthony F. Hadfield
  • METHODS FOR THE PREPARATION OF HYDROXY-SUBSTITUTED ARYL SULFAMIDE COMPOUNDS
    Publication number: 20090156826
    Abstract: The present invention is directed to processes for the preparation of hydroxy-substituted aryl sulfamide derivatives of the formula I or pharmaceutically acceptable salts, stereoisomers or tautomers thereof, which are monoamine reuptake inhibitors wherein the constituent variables are as defined herein.
    Type: Application
    Filed: December 11, 2008
    Publication date: June 18, 2009
    Applicant: Wyeth
    Inventors: Maria Papamichelakis, Jacqueline Francesca Lunetta, Mark Lankau, Luc Richard, Christopher Kendall, Marcelo Cesar Saraiva, Xianghui Wen, Mahmoud Mirmehrabi, Valerie Paquet, Sylvain Daigneault, Puwen Zhang
  • Pharmaceutical dosage forms and compositions
    Publication number: 20070099931
    Abstract: The invention relates to, for example, novel formulations and methods for the delivery of 4-cyano-N-{(2R)—2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-N-pyridin-2-yl-benzamide, pharmaceutically acceptable salts thereof, structurally related compounds and/or metabolites; as well as to use of these formulations and methods for treating disease.
    Type: Application
    Filed: September 6, 2006
    Publication date: May 3, 2007
    Applicant: Wyeth
    Inventors: Krishnendu Ghosh, Arwinder Nagi, Xiaohong Pan, Melissa Lin, Leonid Linberg, Ping Cai, Eric Browne, Michel Bernatchez, Mark Lankau, Sangeeta Raje
  • Crystalline and amorphous 4-cyano-N-{(2R)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin -1-yl]-propyl}-N-pyridin-2-yl-benzamide hydrochloride
    Publication number: 20070027162
    Abstract: The present invention is directed to crystal and amorphous forms of the 5-HT1A receptor antagonist 4-cyano-N-{(2R)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-N-pyridin-2-yl-benzamide hydrochloride, as well as compositions thereof and methods of using the same.
    Type: Application
    Filed: February 27, 2006
    Publication date: February 1, 2007
    Applicant: Wyeth
    Inventors: Eric Browne, Michel Bernatchez, Mark Lankau, Abdolsamad Tadayon, Anthony Hadfield
  • Pharmaceutical dosage forms and compositions
    Publication number: 20050215561
    Abstract: This invention relates to, for example, novel formulations and methods for the delivery of 4-cyano-N-{(2R)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5yl)-piperazin-1-yl]-propyl}-N-pyridin-2-yl-benzamide, pharmaceutically acceptable salts thereof, structurally related compounds and/or metabolites; as well as to use of these formulations and methods for treating disease.
    Type: Application
    Filed: March 17, 2005
    Publication date: September 29, 2005
    Inventors: Krishnendu Ghosh, Arwinder Nagi, Xiaohong Pan, Melissa Lin, Leonid Linberg, Ping Cai, Eric Browne, Michel Bernatchez, Mark Lankau